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We report an autochthonous human case of tickborne 
encephalitis (TBE) in the Bordeaux area, southwestern 
France. The patient was a farmer who had severe enceph-
alomyelitis. ELISA and neutralization assay of serum and 
cerebrospinal ﬂ  uid established the diagnosis. This potential 
new endemic focus for TBE virus should be further inves-
tigated.
T
ickborne encephalitis (TBE) is the most important hu-
man arboviral infection of the central nervous system 
in Europe and Russia (1,2). The disease is endemic to areas 
where transmission vectors (Ixodes ricinus, I. persulcatus) 
are distributed. During the past 10 years, the incidence of 
the disease has increased, particularly in Lithuania, Germa-
ny, Switzerland, and Poland, and human cases have been 
reported from new areas (3–5; see also www.tbe-info.com/
tbe.aspx). Tickborne encephalitis viruses (TBEV), such as 
dengue, yellow fever, West Nile, and Japanese encephali-
tis viruses, belong to the family Flaviviridae. Among the 
TBEV, 3 genotypes have been described (6): the European 
subtype transmitted by I. ricinus and the Siberian and Far 
Eastern subtypes transmitted by I. persulcatus. Large mam-
mals, such as goats, sheep, and cattle, are important blood-
feeding hosts for adult ixodid ticks. Because the virus is 
excreted in milk, small outbreaks may result from consump-
tion of raw milk from sheep or goats. To our knowledge, 
only viruses of the western genotype have been isolated 
in Western Europe. In central and Western Europe, cases 
occur between April and November, and peak in June–July 
and September–October in relation to tick activity (1,2). 
The progression of incidence follows the development of 
tourism, trekking, and camping/hiking in virus-endemic 
countries (3). The European subtype virus usually produces 
a biphasic illness. The incubation period lasts an average of 
7–14 days (range 2–28 days). Primary infection is gener-
ally associated with a ﬂ  ulike syndrome, but infection may 
be asymptomatic (40% of cases). In 5%–30% of clinical 
cases, a second neurologic phase may occur with aseptic 
meningitis (50% of the cases), meningoencephalitis (40%), 
or meningoencephalomyelitis (10%) (1,2,7,8). The Far 
Eastern subtype TBEV infections are considered to be as-
sociated with more severe cases (mortality rate 10%–20%) 
and more frequent neurologic sequelae (5%–30%) (1). 
Speciﬁ  c diagnosis depends essentially on the detection of 
immunoglobulin M (IgM) antibodies in serum or cerebro-
spinal ﬂ  uid (CSF) by ELISA (9).
In France, 5–10 cases of TBE are reported each year. 
Cases have been mainly reported since 1968 from Alsace-
Lorraine in northeastern France (2). We report here the ﬁ  rst, 
to our knowledge, autochthonous case from the Aquitaine 
region in southwestern France.
The Case
On May 28, 2006, a 70-year-old farmer, living in the 
area of Bordeaux, southwestern France, was admitted, fe-
brile and comatose, to the intensive care unit of the “Pel-
legrin hospital” in Bordeaux. He had no relevant medical 
history and had not traveled abroad during the previous 
year. The fever had begun 36 hours earlier, accompanied 
by headache, nausea, and vomiting. An attached tick had 
been removed from patient’s thigh during the previous 
week. He had no history of unpasteurized milk consump-
tion. Physical examination found a temperature of 38.5°C 
and tachycardia. The patient had an altered consciousness 
with a Glasgow Coma Score of 7. He exhibited normal os-
teotendinous and cranial nerve reﬂ  exes, had no Babinski 
sign but had notable nuchal rigidity. Assisted ventilation 
was needed. A blood sample was collected at admission 
and showed the following: leukocyte count 10,300/mm3 
(neutrophils 7,180/mm3, lymphocytes 1,140/mm3); hemo-
globin 14.2 g/L, platelet count 209,000/mm3, creatinine 
158 μmol/L, prothrombin rate 94%. The cerebrospinal ﬂ  uid 
(CSF) ﬁ  ndings were consistent with viral meningoenceph-
alitis: leukocyte count 620 cells/mm3, 45% lymphocytes, 
protein 1.25 g/L, glucose 0.6 g/L. The patient was treated 
with 12 g/day intravenous amoxicillin and acyclovir. On 
day 4, the Glasgow Coma Score was 15, but the patient 
exhibited hypotonic tetraplegia with no osteotendinous re-
ﬂ  exes. Magnetic resonance imaging showed cervicoarthro-
sis myelopathy but no sign of myelitis. An electromyograph 
conﬁ  rmed the diagnosis of peripheral polyneuropathy. Ten 
days later, rapid motor improvement of lower extremities 
was observed, and the patient was transferred on day 15 to 
a rehabilitation center. An incapacitating brachial diplegia 
with amyotrophy persisted after 6 months.
For diagnostic purpose, paired serum samples were 
analyzed. No IgM or IgG antibodies were detected against 
Borrelia spp., Leptospira spp., Mycoplasma spp., Rickettsia 
spp., Brucella spp., Treponema pallidum, HIV, hepatitis B 
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virus, and hepatitis C virus. Results of PCR assays of CSF 
were negative for Borrelia spp., Enterovirus, Adenovirus, 
varicella-zoster virus, herpes simplex virus, Epstein-Barr 
virus, and cytomegalovirus. IgM capture and IgG indirect 
in-house assays with native antigen (from Hypr 1953 TBEV 
strain, kindly provided by F. Heinz) were performed to de-
tect IgM and IgG TBEV antibodies. The cut-offs were as 
follows: IgG cut-off 0.05; IgM cut-off 0.2. An 80% plaque-
reduction neutralization test (PRNT80) was performed by 
using the Hypr 1953 strain to determine the titer of TBEV 
neutralizing antibodies. Rising TBEV IgG optical density 
values were detected in a single assay between the earliest 
and the latest serum specimen (Table). High titers of TBEV 
neutralizing antibodies were detected on days 11 and 24 
after clinical onset of disease (Table). A nested reverse 
transcription–PCR  (10) for TBEV in early serum and CSF 
(days 3 and 4) showed negative results. No TBEV could be 
isolated by culture on Vero E6 cells.
Conclusions
We describe, to our knowledge, the ﬁ  rst case of tick-
borne encephalitis in southwestern France. High levels of 
TBEV IgM were observed in serum and CSF samples, as is 
usually observed in TBE neurologic cases (9). In addition, 
the high titers of TBEV-speciﬁ  c antibodies, determined by 
PRNT, reinforces the conclusion that TBEV is the prob-
able cause of the encephalitis-like condition of the patient. 
However, no virus was isolated and no genome detected. 
Early CSF and serum specimens had not been immediately 
tested for TBEV, and the successive freezing and thawing 
may explain the negative results. Another explanation could 
be that the ﬁ  rst phase of the disease was not recognized by 
the patient and that the viremic phase was already ﬁ  nished 
when the patient was hospitalized, as suggested by the pres-
ence of high titers of TBEV-neutralizing antibodies on day 
8 after admission. This explanation is compatible with the 
chronic exposure of the farmer to tick bites. As a differential 
diagnosis, infection by Borrelia garinii, which is also trans-
mitted by I. ricinus, could be excluded because no speciﬁ  c 
IgM and IgG were detectable by serologic testing and no 
dermatologic signs characteristic of Lyme disease were vis-
ible. However, 2 other tickborne viruses, genetically related 
to TBEV, could not be formally excluded: Louping ill virus 
and Spanish sheep encephalitis virus.
To date, in France most TBE cases have been reported 
from Alsace-Lorraine. However, in 2003, 3 cases were re-
ported from the French Alpen region (5), likely linked to 
goat cheese consumption. These new cases raised the ques-
tion of the extension of TBEV that is endemic in France, 
as has been observed in Germany and Switzerland. Since 
2003, however, patients from this region with meningitis 
and encephalitis have been more systematically screened 
for TBEV, and no other case has been identiﬁ  ed (I. Schuffe-
necker, unpub. data). 
The discovery of the ﬁ  rst TBE case in southwestern 
France raises the question of the mode of emergence of 
the virus in this region. The viral cycle involves mainly ro-
dents or deer and ticks with humans as accidental hosts. 
Domestic ruminants act more as tick transporters than as 
a reservoir. One hypothesis to the emergence could be the 
introduction of infected ticks through animal transportation 
or bird migration. A ﬁ  eld survey in the close vicinity of 
the farmer’s house and ﬁ  elds could yield valuable results. 
Collecting ticks and rodents could provide the opportunity 
to identify the circulating strains (as recently was done in 
Finland and Estonia) (11). Also, a seroprevalence study on 
domestic animals could provide information on the level of 
circulation of ﬂ  aviviruses.
Finally, TBEV should be more systematically screened 
for in patients with encephalitis and meningitis in the ab-
sence of any other etiologic diagnosis. Because this ﬁ  nding 
has implications for expanding vaccine coverage to forest-
ry and agriculture workers, additional epidemiologic data 
about TBEV circulation in southwestern France should be 
obtained.
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RT-PCR (10) Virus culture 
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